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Summary
Background: The management of end stage heart failure has been revolutionized by 
the use of mechanical circulatory support. The Levitronix Centrimag ventricular assist 
device (VAD) is designed for short-term cardiac assistance as a bridge to a more perma-
nent solution to the hemodynamic problem. It has been used as bridge-to-transplantati-
on, bridge-to-bridge, bridge-to-recovery, and bridge-to-decision.
Methods: In the period between September 2008 and November 2009, six patients 
received mechanical cardiac assistance with the Levitronix Centrimag device at our 
institution. In one patient, the indication was postcardiotomy cardiogenic shock. In the 
remaining five patients, the device was implanted electively, due to progressive decom-
pensation of chronic heart failure unresponsive to medical therapy. 
Results: The patient having received a biventricular assist device (BIVAD) in the 
postcardiotomy setting was 65 years of age. His ejection fraction and EuroSCORE were 
20 % and 25, respectively. His NT-pro-BNP was 9,428 pg/ml and his pre-implantation 
lactate was 8.8 mmol/L. The mean age in the group of patients, in whom the VAD was 
placed due to decompensated severe heart failure (DSHF), was 46 ± 11 years. Their 
ejection fraction and logistic EuroSCORE were 16 ± 2 % and 28 ± 7, respectively. The 
preoperative serum lactate and NT-pro-BNP concentrations were 1.7±0.8 mmol/L and 
9577 ± 3674 pg/ml, respectively. Of these, three patients had evidence of end organ 
dysfunction. The low cardiac output was responsible for acute renal failure, requiring 
renal replacement therapy in one patient. Neurocognitive dysfunction and renal fa-
ilure not requiring dialysis was seen in another. The third patient had long standing 
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primary hepatic insufficiency. A reversal of end organ dysfunction was seen in the for-
mer two patients, whereas the hepatic insufficiency was not caused by hemodynamic 
compromise and was, therefore, not relieved by circulatory support. The single patient, 
who had suffered from postcardiotomy cardiogenic shock, died shortly after receiving 
mechanical circulatory support. Three of five patients, in whom Levitronix Centrimag 
was placed electively, were successfully transplanted. The remaining two died of septic 
complications. In the cohort of patients, in whom ventricular assistance was placed 
due to DSHF, two required BIVAD placement, and three left ventricular assist devices 
(LVAD).
Conclusion: The Levitronix Centrimag VAD is useful in supporting circulation in 
patients with acute decompensation of congestive heart failure. It may also be used in 
patients with postcardiotomy shock. It is an imperative for the device to be placed befo-
re irreversible organ dysfunction occurs as the aftermath of malperfusion. 
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INTRODUCTION
The progress in pharmacological therapy has yielded significant improvements 
in the care of patients with heart failure. This has further been facilitated by the 
utilization of devices such as cardioverter/defibrillators and cardiac resynchroniza-
tion therapy [1]. While heart transplantation remains an excellent therapeutic option 
for patients with terminal heart failure, it is available only to a minority of poten-
tial transplant candidates due to a shortage of organ donors [2]. The discrepancy 
between the number of heart transplantations and the number of patients, who co-
uld benefit from this form of therapy, provides a fertile milieu for the development 
of mechanical assist devices. Ventricular assist devices are now viable options for 
patients with severe heart failure symptoms as bridge-to-transplantation, bridge-
to-decision, bridge-to-recovery, or as destination therapy. Various mechanical assist 
devices differ widely in the intended recipient patient populations. The Centrimag 
device (Levitronix, Waltham, MA, USA) is a contemporary adjunct to the available 
spectrum of short-term mechanical assist devices. It has been utilized in patients 
with refractory cardiogenic shock for either univentricular or biventricular support 
[3,4]. It has also been used for the purpose of extracorporeal membrane oxygenati-
on [5]. The Levitronix Centrimag device is a new generation pump that offers he-
modynamic support with reduced blood trauma. It does not contain rotating bea-
rings or seals. It is also devoid of flexing valves or diaphragms. When compared to 
older generation centrifugal pumps, this technical design allows for longer circula-
tory support. Its dominant feature is a magnetically levitated rotor, which is not in 
contact with the housing of the device.
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PATIENTS AND METHODS
In six patients, short-term mechanical circulatory support was instituted using 
the Levitronix Centrimag device between September 2008 and November 2009 at 
the University Hospital Rebro Zagreb. The records of these patients were reviewed. 
In one patient, the device was implanted in the setting of prolonged postcardiotomy 
cardiogenic shock. In five patients, the indication for ventricular assistance was de-
compensated severe heart failure (DSHF). These patients were analyzed separately, 
since the clinical settings were quite different. The patient in postcardiotomy shock 
received biventricular assist device placement (BIVAD). Of the five elective patients, 
who suffered from decompensated severe heart failure, three underwent solely left 
ventricular assistance, whereas in the remaining two a BIVAD was placed.
Technical considerations
The components of the Centrimag system include a centrifugal blood pump, 
a motor, a console and a flow probe. The magnetic force, generated by the motors, 
levitates the impeller in the pump housing in addition to creating the torque that 
translates into unidirectional flow out the device. The priming volume is 31 ml. 
Implantation technique 
The device was inserted through a median sternotomy in all patients. In three 
patients, the Centrimag was implanted for biventricular support, and in the remai-
ning three patients, only the left ventricle was assisted. In three patients, the device 
was implanted with the use of cardiopulmonary bypass (CPB). The decompression 
of the heart made the placement of the left atrial and pulmonary artery cannulae 
simpler in those cases. In the remaining three patients, the Centrimag was implan-
ted without CPB. All patients received a bolus dose of heparin, in order to achieve 
an activated clotting time greater than 450 seconds prior to the implantation. Anti-
fibrinolytic therapy with tranexamic acid was administered to every patient. All ca-
nnulae were placed through two 2/0 Prolene purse-string sutures, reinforced with 
Teflon pledgets. The sizes of individual cannulae were tailored to the patient body 
surface area. Intraoperatively, heparin was fully reversed with protamine after the 
ventricular assistance had commenced.
Postoperative management
Anticoagulation with intravenous heparin was started 12-24 hours after the im-
plantation of the Centrimag, provided that the chest tube output was minimal. The 
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target ACT was 180 to 200 seconds. Once the patients achieved hemodynamic sta-
bility in the intensive care unit, their sedation was discontinued, and subsequently, 
they followed the standard protocols for weaning off mechanical ventilation.
RESULTS
Six consecutive patients, undergoing Centrimag ventricular assistance, were 
included into our study. The patient demographic data are presented in Table 1. 
The patient, who underwent the salvage placement of the Centrimag device in the 
setting of postpericardiotomy shock, is presented isolated from the remaining five 
patients, since his clinical scenario differed greatly from the remaining patients. 
Irreversible organ dysfunction was likely present at the time of the ventricular assist 
Table 1. Preoperative patient characteristics
PCS* DSHF**
N 1 5
Age (yrs) 65 46±11
Gender (n/%)
    Male 1 (100) 4 (80)
    Female 0 (0) 1 (20)
Ejection fraction 20 16 ± 2
EuroSCORE 25 28 ± 7
DDRF 0 1 (20)
Non-DDRF 0 1 (20)
Hepatic failure 0 1 (20)
Neurocognitive dysfunction 0 1 (20)
Inotropes  1 (100) 5 (100)
Sodium ion (mmol/L) 135 127±9
Bilirubin 40 29±22
Alkaline phosphatase (IU/L) 119 178±245
Alanine aminotransferase (IU/L) 143 171±271
Urea (mmol/L) 12 12±5
Creatinine (mmol/L) 109 154±116
Mechanical ventilation  1 (100) 0 (0)
Lactate (mmol/L) 8.8 1.7±0.8
PCS = Postcardiotomy cardiogenic shock
DSHF = Decompensated severe heart failure
DDRF = Dialysis-dependant renal failure
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device placement, which was instituted as salvage therapy. The patient was reope-
rated for bleeding on multiple occasions, due to a severe and resistant coagulopathy, 
and died within 24 hours of placing the device.
In the cohort of patients with decompensated severe heart failure (n=5), the 
mean duration of support was 21±23 days. The mean duration of ventilatory support 
was 14±6 hours. All patients remained in the intensive care unit for the duration of 
the ventricular assistance. One patient had to be taken back to the operating room 8 
days after the implant procedure for bleeding. She was found to have an iatrogenic 
intercostal artery injury after a pleural tap had been performed. This was unrelated 
to the placement of the device. There were no permanent strokes.
Three of these five patients suffered from some degree of end-organ dysfuncti-
on prior to the placement of the device. In one patient, in whom the renal function 
recovered after the placement of the Centrimag as an LVAD up to a point where 
he could be weaned off renal replacement therapy, it was dialysis-dependant renal 
failure. The neurocognitive function in a second patient also improved upon the in-
stitution of Centrimag support. This patient also had non-dialysis-dependant renal 
failure, which did not show any significant improvement following VAD placement. 
The hepatic failure, seen in another one of the patients, did not improve with the 
Table 2. Perioperative data
PCS* DSHF**
N 1 5
Duration of VAD support (days) 1 21±23
Mechanical ventilation (hrs) 20 14±6
Lactate POD 1 (mmol/L) > 15 1.2±0.4
BIVAD 1 (100) 2 (40)
LVAD 0 3 (60)
Off pump placement 0 3 (60)
Duration of CPB (min) 281 37±20
Cerebrovascular incident Unknown 0 (0)
DDRF 1 (100) 0 (0)
Bleeding (resternotomy) 1 (100) 1 (20)
Mortality 1 (100) 2 (40)
Bridge to transplantation 0 (0) 3 (60)
VAD = ventricular assist device
BIVAD = biventricular assist device
POD1 = postoperative day 1
CPB = cardiopulmonary bypass
DDRF = Dialysis-dependant renal failure
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hemodynamic support. This patient suffered from hemochromatosis and had in-
trinsic liver failure. He underwent successful heart tranplantation after having been 
supported on the Centrimag for 11 days, and is currently being evaluated for liver 
transplantation. Three of the five patients with decompensated severe heart failure 
underwent heart transplantation. There were no deaths following the transplant 
procedure. The remaining two patients on Centrimag support, who were not tran-
splanted, died. One died after 9 days of Centrimag LVAD support of pulmonary 
complications that progressed to septic shock. The device was supporting the se-
cond patient in this cohort, who died, for 62 days. She was initially found to have a 
panel reactive antibody (PRA) titer in excess of 90 %. The process of desensitization 
included the treatment with plasmapheresis, intravenous immunoglobulins and ri-
tuximab. Unfortunately, the PRA titer remained high, and the patient ultimately 
developed a sepsis with subsequent multiple organ failure, which led to death. De-
tailed perioperative data are presented in Table 2. 
DISCUSSION
The challenges of heart transplantation include organ donor shortages; complex 
immunobiologic responses leading to acute rejection; complications of immunosu-
ppressive treatment; and organ failure due to chronic rejection and allograft vas-
culopathy [1]. The limitations of transplant surgery have invoked innovations in 
VAD designs, making devices increasingly more appealing for the management of 
severe heart failure. The ventricular assist devices vary greatly, in terms of durati-
on of intended support; type of flow augmentation; levels of possible ambulation; 
hence, they are designed for various patient populations. The Levitronix Centrimag 
is a short-term VAD, designed as a bridge-to-recovery, bridge-to-decision, bridge-to-
bridge or bridge-to-transplantation [4,6]. We have found its versatile design simple 
to operate and useful in the settings of both uni- or biventricular failure. It has the 
ability to reverse end-organ dysfunction, provided that the potential for its reco-
very still exists. The level of ambulation these patients can achieve is limited, but 
physical therapy is nevertheless critical to the successful management of these pa-
tients. We have instituted the Centrimag support as a bridge-to-transplantation in 
five patients, and as a bridge-to-decision in the scenario of postcardiotomy shock in 
one patient. Three patients were successfully transplanted and have been dischar-
ged home. Our small series illustrates the feasibility of using the concept of short-
term mechanical assistance in patients with severe decompensated heart failure as 
a bridge-to-transplantation, allowing for recovery of end-organ function secondary 
to malperfusion. This, in turn, allows for the transplant procedure to be performed 
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in optimal conditions for the patients. The device certainly has the potential to be 
used in the postcardiotomy failure scenario. It is paramount, however, to institute 
circulatory support prior to the development of irreversible end-organ damage. 
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Sažetak
Rezultati ugradnje Levitronix Centrimag mehaničke potpore srcu u Kliničkom bolničkom 
centru Zagreb
Uvod: Liječenje terminalne faze srčanog popuštanja je revolucionarizirano uvođenjem me-
haničke potpore srcu. Levitronix Centrimag je uređaj dizajniran u svrhu kratkoročne hemodi-
namske potpore prije nego što trajnije rješenje cirkulatornog problema postane moguće. Do sad 
se primijenjivao kao podrška srcu do transplantacije srca,  do oporavka srčane funkcije ili do 
ugradnje trajnijeg oblika mehaničke potpore srcu. 
Metode: U periodu između rujna 2008 i studenog 2009 Levitronix Centrimag je u našoj 
ustanovi ugrađen u 6 bolesnika. U jednog bolesnika radilo se o postkardiotomijskom sindromu 
niskog minutnog volumena. U preostalih pet bolesnika ovaj je oblik mehaničke potpore srcu 
ugrađen elektivno radi progresivnog kliničkog pogoršanja bolesnika u terminalnoj fazi srčanog 
popuštanja koje je postalo rezistentno na konzervativnu terapiju. 
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Rezultati: Bolesnik u kojeg je indikacija za mehaničkom potporom srcu bila postavljena hit-
no u postkardiotomijskom srčanom popuštanju bio je 65 godina star. Imao je ejekcijsku frakciju 
od 20% dok mu je logistički EuroSCORE bio 25. Prijeoperacijski NT-pro-BNP bio je 9428 pg/
ml dok su serumske vrijednosti laktata prije implantacije Centrimaga bile 8.8 mmol/L. Prosječna 
dob u skupini bolesnika u kojih je indikacija za mehaničku potporu srcu bila progresivna dekom-
penzacija srčane funkcije bila je 46 ± 11 godinu. Navedeni bolesnici su imali prosječnu ejekcij-
sku frakciju od 16 ± 2% dok im je logistički EuroSCORE bio 28 ± 7. Prijeoperacijske vrijednosti 
serumskog laktata i NT-pro-BNP bile su 1.7±0.8 mmol/L i 9577 ± 3674 pg/ml. U troje bolesnika 
bila je evidentna kompromitacija funkcije nekog od ostalih organskih sustava. U jednog bolesni-
ka se radilo o akutnom renalnom zatajenju ovisnog o hemodijalizi, u drugog o neurokognitivnoj 
disfunkciji praćenog sa bubrežnim zatajenjem ali bez potrebe za dijalizom. U trećeg bolesnika 
radilo se o primarnoj hepatalnoj insuficijenciji. U prva dva bolesnika došlo je do poboljšanja 
organskih funkcija nakon uspostave mehaničke potpore srcu, dok u trećeg bolesnika nije došlo 
do promjene hepatalne funkcije budući da ista nije bila uzrokovana malperfuzijom. Bolesnik u 
kojeg je mehanička potpora srcu stavljena zbog postkardiotomijskog kardiogenog šoka je umro. 
Troje od pet bolesnika kod kojih je Levitronix Centrimag ugrađen radi dekompenzacije kronič-
nog zatajenja srca su uspješno transplantirani. Preostalo dvoje bolesnika je umrlo od septičnih 
komplikacija. U kohorti bolesnika u kojoj je mehanička potpora srcu ugrađena elektivno, dvoje 
bolesnika je zahtijevalo potporu oba ventrikula dok je u troje ugrađena potpora samo lijevom.
Zaključak: Levitronix Centrimag pruža efikasnu hemodinamsku potporu bolesnicima sa 
kompromitiranom srčanom funkcijom. Neophodno je započeti sa mehaničkom potporom srcu 
prije nego što se pojave ireverzibilne disfunkcije ostalih organskih sustava. 
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